Keeping an Eye on Emerging Anti-VEGF Therapies & Improved Outcomes

CME

Updates in Retinal Disease Care: Keeping an Eye on Emerging Anti-VEGF Therapies & Improved Outcomes

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Released: December 20, 2022

Expiration: December 20, 2023

Pretest

Progress
1 2
Course Completed
1.

What percentage of patients with nAMD are undertreated in the first year of therapy? 
Answers

2.

Which statement is most accurate regarding the efficacies of aflibercept, bevacizumab, ranibizumab, as AMD therapies? 

3.

Which statement best describes the results from the phase 3 trials of faricimab vs. aflibercept in patients with DME? 

4.

Which statement best describes the results of the phase 3 trial of the port delivery system for patients with nAMD?